Lyra Issuance Of Capital Stock from 2010 to 2024

LYRA Stock  USD 0.31  0.01  3.13%   
Lyra Therapeutics' Issuance Of Capital Stock is increasing over the years with slightly volatile fluctuation. Overall, Issuance Of Capital Stock is expected to go to about 73.5 M this year. From 2010 to 2024 Lyra Therapeutics Issuance Of Capital Stock quarterly data regression line had arithmetic mean of  47,074,762 and r-squared of  0.50. View All Fundamentals
 
Issuance Of Capital Stock  
First Reported
2010-12-31
Previous Quarter
50 M
Current Value
73.5 M
Quarterly Volatility
28.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lyra Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyra Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 4.3 M, Interest Income of 4.3 M or Depreciation And Amortization of 264.1 K, as well as many indicators such as Price To Sales Ratio of 106, Dividend Yield of 0.0 or PTB Ratio of 2.77. Lyra financial statements analysis is a perfect complement when working with Lyra Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Lyra Therapeutics Correlation against competitors.
For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.

Latest Lyra Therapeutics' Issuance Of Capital Stock Growth Pattern

Below is the plot of the Issuance Of Capital Stock of Lyra Therapeutics over the last few years. It is Lyra Therapeutics' Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lyra Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Issuance Of Capital Stock10 Years Trend
Slightly volatile
   Issuance Of Capital Stock   
       Timeline  

Lyra Issuance Of Capital Stock Regression Statistics

Arithmetic Mean47,074,762
Geometric Mean40,858,491
Coefficient Of Variation60.88
Mean Deviation23,914,083
Median29,000,000
Standard Deviation28,657,543
Sample Variance821.3T
Range71.5M
R-Value0.71
Mean Square Error443.2T
R-Squared0.50
Significance0
Slope4,525,997
Total Sum of Squares11497.6T

Lyra Issuance Of Capital Stock History

202473.5 M
202350 M
2021100.5 M
202090.3 M
201930.4 M

About Lyra Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lyra Therapeutics income statement, its balance sheet, and the statement of cash flows. Lyra Therapeutics investors use historical funamental indicators, such as Lyra Therapeutics's Issuance Of Capital Stock, to determine how well the company is positioned to perform in the future. Although Lyra Therapeutics investors may use each financial statement separately, they are all related. The changes in Lyra Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lyra Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lyra Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lyra Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Issuance Of Capital Stock50 M73.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Lyra Stock

When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:
Check out the analysis of Lyra Therapeutics Correlation against competitors.
For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Revenue Per Share
0.03
Quarterly Revenue Growth
0.298
Return On Assets
(0.38)
Return On Equity
(0.96)
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.